Comment on: Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.
作者信息
Mégarbane Bruno, Scherrmann Jean-Michel
机构信息
Department of Medical and Toxicological Critical Care, Lariboisière Hospital, Federation of Toxicology APHP, University of Paris, INSERM UMRS-1144, Paris, France.
Faculty of Pharmacy, University of Paris, INSERM UMRS-1144, Paris, France.
出版信息
J Antimicrob Chemother. 2021 Jan 1;76(1):276-277. doi: 10.1093/jac/dkaa327.
Abstract
摘要
相似文献
1
Comment on: Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.
J Antimicrob Chemother. 2021 Jan 1;76(1):276-277. doi: 10.1093/jac/dkaa327.
2
Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.
J Antimicrob Chemother. 2020 Sep 1;75(9):2376-2380. doi: 10.1093/jac/dkaa191.
3
Comment on: COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
J Antimicrob Chemother. 2020 Jul 1;75(7):2016-2017. doi: 10.1093/jac/dkaa169.
4
Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial-authors' response.
J Antimicrob Chemother. 2021 Jan 1;76(1):277-279. doi: 10.1093/jac/dkaa415.
5
Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit.
Ann Rheum Dis. 2020 Jun;79(6):e62. doi: 10.1136/annrheumdis-2020-217524. Epub 2020 Apr 23.
6
Does hydroxychloroquine combat COVID-19? A timeline of evidence.
J Am Acad Dermatol. 2020 Jul;83(1):e33-e34. doi: 10.1016/j.jaad.2020.04.031. Epub 2020 Apr 10.
7
Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline.
RMD Open. 2020 Oct;6(3). doi: 10.1136/rmdopen-2020-001323.
8
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.
Int J Antimicrob Agents. 2020 Apr;55(4):105932. doi: 10.1016/j.ijantimicag.2020.105932. Epub 2020 Mar 4.
9
Does hydroxychloroquine prevent the transmission of COVID-19?
Ann Rheum Dis. 2020 Jun;79(6):e60. doi: 10.1136/annrheumdis-2020-217501. Epub 2020 Apr 15.
10
Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU.
Trials. 2020 Jul 8;21(1):631. doi: 10.1186/s13063-020-04566-x.
本文引用的文献
1
Hydroxychloroquine pharmacokinetic in COVID-19 critically ill patients: an observational cohort study.
Intensive Care Med. 2020 Sep;46(9):1772-1773. doi: 10.1007/s00134-020-06142-y. Epub 2020 Jun 8.
2
Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.
J Antimicrob Chemother. 2020 Sep 1;75(9):2376-2380. doi: 10.1093/jac/dkaa191.
3
Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.
Clin Pharmacol Ther. 2020 Oct;108(4):775-790. doi: 10.1002/cpt.1909. Epub 2020 Jun 14.
4
Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019.
Clin Infect Dis. 2020 Dec 15;71(12):3232-3236. doi: 10.1093/cid/ciaa623.
5
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.
BMJ. 2020 May 14;369:m1849. doi: 10.1136/bmj.m1849.
6
Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome.
J Pharmacokinet Pharmacodyn. 2020 Jun;47(3):187-188. doi: 10.1007/s10928-020-09689-x. Epub 2020 May 13.
7
Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.
Clin Pharmacol Ther. 2020 Aug;108(2):253-263. doi: 10.1002/cpt.1856. Epub 2020 May 12.
8
Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection.
Clin Transl Sci. 2020 Jul;13(4):642-645. doi: 10.1111/cts.12797. Epub 2020 May 9.
9
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.
Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020.
10
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
Zotero 插件